| Autor: |
Lehne, Moritz, Kortüm, K. Martin, Ramasamy, Karthik, Zamagni, Elena, d'Estrubé, Tim, Zhuleku, Evi, Hanna, Maya, Shukla, Soham, Ghiani, Marco, Maywald, Ulf, Wilke, Thomas, Kellermann, Lenka, Perera, Sue |
| Předmět: |
|
| Zdroj: |
European Journal of Haematology; May2024, Vol. 112 Issue 5, p701-713, 13p |
| Abstrakt: |
Objectives: To retrospectively analyze real‐world treatment patterns in patients with relapsed/refractory multiple myeloma (RRMM) who initiated third‐line treatment in Europe. Methods: German and Italian administrative claims data were sourced from the German AOK PLUS health insurance fund and Italian local health units (2016–2020). Data for the United Kingdom (UK), France, and Spain were sourced from medical chart reviews (MCRs) from 2016 to 2018 (historical) and 2019 to 2021 (new) using electronic case report forms. Results: Across all countries, immunomodulatory imide drug (IMiD)‐based regimens were prominent in the third‐line setting. From 2016 to 2020, lenalidomide‐dexamethasone was most common in Italy (18.0%) and Germany (12.7%). From 2019 to 2021, the most common regimen was ixazomib‐lenalidomide‐dexamethasone (67.5%) in the UK, pomalidomide‐dexamethasone (17.1%) in France, and daratumumab‐bortezomib‐dexamethasone (15.0%) in Spain. In the historical data (2016–2018), third‐line lenalidomide‐ and pomalidomide‐dexamethasone doublet use across the UK (>47%), France (>46%), and Spain (>33%) was high. From historical to new, triplet use increased in Spain (>19% to >60%) as did anti‐CD38 agent use in France (15.1% to 51.9%) and Spain (19.7% to 42.1%). Conclusions: From 2016 to 2021, third‐line regimens were mostly IMiD based. The MCR data demonstrated evolving treatment choices from 2016 to 2018 and 2019 to 2021, providing insights into uptake of novel agents and current RRMM European clinical practice. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text